Hibernia College Dublin

Live. Learn.

M.Sc. in Pharmaceutical Medicine

Master of Science in Pharmaceutical Medicine (MSc)

Hibernia College, in partnership with personnel from Pfizer, Novartis, Sanofi, Quintiles, Icon, Lincoln Research, the EMA, the MCC of South Africa, Eupati, IE Business School, TCD, UWC, University of Basel and the Medical University of Vienna has developed the MSc in Pharmaceutical Medicine, a 100% online work-based program that has been described as the ‘Executive MBA of the pharmaceutical industry’.

From Molecule to Medical Application

The two year Master of Science in Pharmaceutical Medicine is suitable for employees in the pharmaceutical, drug development and health-care industries and will give you the essential skills to solve the medical, scientific and economic challenges in today’s industry. You will systematically understand the drug development process from discovery through research and development to regulatory approval and commercialization.

Flexible Pharmacology Study

The program is a 100% online study of pharmacology and clinical trial management within pharmaceutical medicine. It is highly flexible to help balance work, life and study and while the entire masters program takes 2 years, students can take 6 month certificates that build towards the full award.

Global Drug Development Network

Due to the online nature of this program you are interacting with professionals, like yourself, from all over the world. Your studies do not require you to travel or to take any time off work and your company knows you receive the same education whether based in Boston or Bangalore.

Our students come from areas such as medical and regulatory affairs, product and portfolio management, pharmacology, clinical research and drug development, clinical trial management, preclinical research, drug safety, pharmacoeconomics, marketing and market access.

Graduates from industry leaders

With graduates from over 45 countries working with Pfizer, Novartis, the EMA, Roche, Biogen, Johnson and Johnson, Bayer, Astra Zeneca, Leo, Ranbaxy, generic companies and CRO’s:  you will join a truly valuable network, especially when you consider graduates have become Vice President’s in Medical Affairs, Global Heads of Quality Assurance, Regional Medical Directors and elected to scientific advisory boards within their organizations.

Leading international faculty

The Master of Science in Pharmaceutical Medicine from Hibernia College brings to your workplace leading international faculty from industry, regulatory agencies and academia to create a learning experience that will help you to take advantage of the opportunities emerging in the pharma industry.

100% Online

The Master of Science in Pharmaceutical Medicine is delivered 100% online through two main forms of e-learning: online lessons and engaging tutorials, allowing you to study the course wherever you are and, as much as possible, at the times that suit you. You can meet fellow students in person at two optional face to face modules. These are currently “Ethics” and “Leadership” and are taught in Dublin and Cambridge, MA.

Highest quality education in drug development

PharmaTrain Centre of Excellence

The Master of Science in Pharmaceutical Medicine was the world’s first IMI Pharmatrain Centre of Excellence, recognizing that our students receive the highest quality education available in drug development.

PharmaTrain is an EU sponsored programme providing a comprehensive solution for the training needs of integrated drug development for all professionals involved in the industry.

This broad-based programme will greatly enhance the skill-sets and competencies of all key contributors to the drug development and regulatory processes using the latest scientific approaches in the development of medicines on pathophysiology, safety and risk-awareness, patient and population-based benefit as well as make the development process faster, more economical and more competitive.

The Innovative Medicines Initiative and PharmaTrain

The Innovative Medicines Initiative (IMI) is a unique partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its aim is to support the faster discovery and development of better medicines for patients and to enhance Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector. For more information about the Innovative Medicines Initiative Pharmatrain project visit www.pharmatrain.eu.

Logo: IFAPP

Hibernia College is a member of the European Federation of Courses in Pharmaceutical Medicine, which in partnership with IFAPP, has won the IMI call 16 (Pharmatrain) tender.

PharmaTrain Centre of Excellence

Key Points

•    Accreditation: QQI, IFAPP, IMI Pharmatrain.
•    Next intake: April 2014
•    Duration: 2  – 5 years.
•    Total Tuition Fees: €18,900*
* A limited number of partial scholarships available to qualified candidates.

 

PharmaTrain Centre of Excellence

Learning Outcomes

Upon successful completion of the Master of Science in Pharmaceutical Medicine, students will be able to:

  • Understand and assess the principal steps in drug discovery
  • Construct a complete development plan (pharmaceutical, non-clinical and clinical) according to the proposed therapeutic indication
  • Evaluate the pertinent issues involved in the undertaking of clinical research
  • Assess the regulation of medicines in the various global markets and understand how differences can effect drug development, manufacturing and marketing
  • Analyse and manage drug safety issues
  • Review and formulate product-related information to ensure adherence to ethical and legal provisions
  • Understand the principles of health economics and their application in the development and marketing of medicines
  • Lead the management of all lifecycle activities including regulatory and marketing of a medicine
  • Demonstrate advanced and innovative research and development skills, taking drug development to the next level in safety, efficacy and cost-efficiency
  • Critically review and interpret the literature relating to drug research and usage
  • Demonstrate expertise in formulating, conducting and reporting an independent and ethical research project in one of the major subject areas of Pharmaceutical Medicine

PharmaTrain Centre of Excellence

Syllabus

Module descriptions

This course consists of 10 discrete modules covering the key disciplines required by leaders in the pharmaceutical industry plus a research project:

Ethics

Ethics gives the participant an understanding and appreciation of ethical issues that currently affect the pharmaceutical and health industries. The purpose of medical research is to benefit society by the systematic acquisition of useful, empirical knowledge driven by a desire to understand the causes of disease or dysfunction and find effective methods of prevention or treatment.

In extreme cases, however, even such humanitarian aims can be risky – especially as the very potential for achieving tangible benefits can feed the temptation to press on beyond acceptable boundaries. Arguments about an anticipated greater good are commonly invoked by those willing to sacrifice the rights of research subjects.

In addition to humanitarian aims, scientific curiosity is another major impetus for experimentation. After all, the achievements of modern medicine stem from research and advances which are now taken for granted and were developed through experimentation. For the most part these were probably responsibly conducted according to the standards and theories available at the time. Some research, however, involves such risk or definite harm for the participants that it clearly falls outside all acceptable parameters. Coerced participation in research is clearly abusive but the lack of opportunity to participate can also be so. These are some of the issues addressed in the course.

On successful completion of this module, participants will be able to:

  • Evaluate the ethical suitability of research methodologies for the purpose of undertaking research in pharmaceutical medicine especially with respect to vulnerable groups
  • Critically review the ethical issues involved in the undertaking of clinical research
  • Recognise the subjectivity in ethical issues which impact on the research of human and non-human subjects and construct reasonable arguments for their own or others opinion
  • Demonstrate the ability to formulate effective and ethical leadership tools in Pharmaceutical Medicine

Core Competencies in Pharmaceutical Medicine

The aim of this module is to introduce participants to the core competencies in Pharmaceutical Medicine to a level where they can identify the key issues affecting the industry, critically analyse them and begin to reflect upon possible solutions and opportunities.

Upon successful completion of this module the participant will be able to:

  • Review the key issues involved in the undertaking of clinical research and development especially in relation to Pharmaceutical Medicine
  • Compare the regulation of medicines in the various global markets
  • Explain the principles of health economics and discuss their application in the development and marketing of medicines

Pharmacovigilence

Pharmacovigilance covers the safety and risk issues that one must address to ensure patients receive safe drugs. This module will give participants a working knowledge of all aspects of drug safety monitoring and risk management and will enable them to predict and analyse drug interactions, and recognise the implications for prescribing and product licence. The participant will also be familiar with pharmacovigilance best practice, including monitoring strategies and action plans and be fully cognisant of regulatory reporting requirements.

At the end of the module, participants should be able to:

  • Appreciate the effect on patient safety and a product’s licence by the different types of adverse events/reactions
  • Identify the key safety reporting requirements, according to the type of adverse event/reaction (in clinical research or in commercial products)
  • Construct and evaluate benefit/risk assessments throughout the lifecycle of a medicine, with reference where applicable to issues around pre- and post-market authorisation

Regulatory Affairs

Regulatory Affairs covers the key regulatory and medical affairs issues affecting the industry today. The course explains the roles of the major regulatory authorities and the regulatory requirements during drug development. Medical information and regulations including prescribing issues and life cycle management are also reviewed in detail.

After successfully completing this module participants will be able to:

  • Evaluate the regulatory issues affecting the pharmaceutical industry
  • Compare the regulation of medicines in different global markets
  • Develop and critically appraise product-related information to ensure adherence to ethical and legal provisions
  • Compare and evaluate the different roles of Regulatory and Medical Affairs departments in order to propose consistent strategies involving the marketing of pharmaceuticals, medical information, the role of a pharmaceutical company’s country medical department and licensing agreements

The 10 lessons cover the following topics:

  • Drug Regulation and the Agencies
  • Regulatory Requirements during Drug Development and Marketing Approval
  • Structure of Marketing Authorisation Applications and the role of ICH
  • Chemistry and Manufacturing Control and New Regulatory Approaches to Qualify
  • Post-Approval Regulatory Affairs
  • Intellectual Property and Lifecycle Considerations of Pharmaceutical Products
  • Principles and Practice of Marketing
  • Medical Information and the Regulations
  • The Country Medical Department
  • Emerging Regulatory Issues in Pharmaceutical Development.

Discovery and Formulation of New Medicines

This module provides participants with a systematic understanding of the principles of pharmacology and the mechanism of the action of drugs. During the course of this module, participants will develop a comprehensive understanding of the stages of drug discovery and the mechanism of the action of drugs and will become familiar with the techniques used to identify new drugs and their targets. Participants will learn how to interpret basic research reports originating from the drug discovery process, to evaluate the data and aid in the selection of candidate compounds.

Participants will also develop an understanding of new areas in drug discovery including proteomics, genomics and molecular modelling, and will be able to use data from a range of different areas to understand the mechanism of the action of a drug. Finally, participants will develop an understanding of pharmacology that will allow them to critically appraise pharmacology data and make recommendations on the suitability of a drug for future studies and for clinical development.

At the end of this module, participants will be able to:

  • Critically appraise the principle steps in drug discovery based on incomplete and often contradictory data and objectives
  • Evaluate the mechanism of the action of drugs and the techniques used to identify new drugs and their targets
  • Make justified recommendations on the suitability of a drug for future studies and clinical development

Drug Development and Therapeutics

This module will give participants a thorough grounding in the early stages of pharmaceutical research from target identification through human pharmacology studies and the examination of the major therapeutic areas. Therapeutics covers the major diseases, their etiology, epidemiology, pathophysiology, current treatments and their mode of action and possible future cures and preventions. Development focuses on the pharmacological effects that medicines have on the body.

Participants will use the skills that they have developed to evaluate data from a range of different studies, such as various toxicology and pharmacology studies, to select appropriate candidate compounds for clinical study and to develop the appropriate clinical strategy.

Upon successful completion of this module, participants will:

  • Comprehend the key principles of the development of new therapies based on un-met medical needs through the critical evaluation of case studies, research papers and/or research data
  • Evaluate the suitability of research methodologies especially in relation to pharmacology and therapeutic research
  • Comprehend the major therapeutic areas, their epidemiology, pathophysiology, diagnosis, treatment and evaluate opportunities for the industry to meet un-met medical needs in the future
  • Synthesize the different rationales for development plans and be able to construct a plan according to a proposed therapeutic indication

Research Methods

Research Methods teaches the participant not only the critical techniques a scientist needs to know when conducting research but also how to write about his or her research. Not only is this relevant for a dissertation but also for publishing in peer-reviewed journals. A significant amount of cutting edge developments in research and development as well as in health economics and indeed operations are done by industry; however, a large amount of this work goes unreported outside of the professional’s own department, never mind his or her organisation. Professionals in industry therefore require the skills to share their work with others, to communicate their learnings, their discoveries and their failures, thus improving research and thus benefiting the industry as a whole and more importantly, the patient.

This module will introduce participants to methodology and techniques required for successful completion of their research project and develop their ability to identify an appropriate research question and formulate a valid hypothesis. It will also enable participants to design their own research project and manage it in a time-dependent manner in addition to helping them to develop practical skills for data analysis and presentation of results suitable for dissertations and research papers.

After successfully completing this module, participants will be able to:

  • Evaluate the suitability of research methodologies for the purpose of undertaking research
  • Critically review and interpret the literature relating to drug research and development
  • Critically review the ethical issues involved in the undertaking of clinical research
  • Formulate and compare methods for data analysis and the presentation of results and compare different methods when presenting different results
  • Demonstrate the ability to write a research paper by completing at least a hypothesis, an abstract and preliminary literature review

Leadership and Negotiation

Designed for professionals in positions of authority or aspiring to such roles, this course generates essential diagnostic and strategic understanding, as well as personal insight and skills for leadership. Participants are introduced to the theory and practice of negotiation in the context of organisational leadership and management. The purpose is to help professionals strengthen their ability to exercise leadership and negotiate successfully.

Drawing from several disciplines, the course develops a framework for diagnosing and intervening in organisational systems to generate adaptive work. This framework will help participants better analyse negotiations in general and prepare more effectively for future negotiations in which they hope to exercise leadership.

The outcomes of this course include the mastery of a set of practical leadership skills. To obtain this outcome, this 5-day course will combine seminar-based sessions with role playing and leadership simulations. The simulation exercises draw from a wide variety of contexts and their aim is to provide concepts and tools that apply to negotiations that require the exercise of leadership. Through analysis of case studies and discussion of articles on leadership, participants will apply the lessons learned to ongoing, real-world cases.

Upon successful completion of this module, participants will:

  • Demonstrate the ability to judge, select and/or formulate effective leadership tools
  • Demonstrate mastery of a set of practical leadership skills
  • Review, evaluate and propose solutions to scenarios typical for leaders in industry and arrive at possible solutions working in a team environment
  • Recognise the subjectivity in ethical and leadership issues and construct reasonable arguments for one’s opinion or recommendations

Clinical Trials, Knowledge Management and Statistics

The Clinical Trial Management module covers the practical management of the development of a medicine from Phase I to IV using the latest agile and adaptive research techniques to optimise efficiency in the development process. It also teaches participants how to critically review and evaluate statistical data and to leverage the information and knowledge created to contribute to the competitive advantage of their organisation. It is a practical course on how to plan and manage clinical trials cognisant of the pharmacoeconomic conditions and leadership challenges the participant will need to address when leading clinical development programs.

After successfully completing this module, participants will be able to:

  • Critically appraise the principle steps in the clinical trial phases that can often be based on incomplete and sometimes contradictory data and objectives
  • Evaluate the suitability of research methodologies for the purpose of undertaking clinical trials as adaptive as possible
  • Critically review the issues (including legal, ethical, clinical and/or commercial) involved when undertaking clinical trials
  • Demonstrate the ability to plan and develop clinical trials in accordance with legislative requirements and Good Clinical Practice (GCP) procedures
  • Critically interpret and manage statistical data used in clinical development and discriminate between relevant and non-relevant data and be able to justify such decisions

Health Economics

This module will provide the participant with an understanding of the economics affecting the pharmaceutical industry. The development of efficacious, safe, high quality, reliable drugs that meet a medical need must be the primary philosophy of pharmaceutical medicine but it cannot be done without reference to Health Economics. The module will review the importance and impact of healthcare in the economic activity, the functioning of the healthcare market and the health insurance market, the functioning of the pharmaceutical sector and the importance of innovation and the problems of incentives in both the supply and demand of healthcare and pharmaceutical products.

At the end of the module, participants will be able to:

  • Evaluate the commercial and pharmaco-economic issues pertaining to drug development
  • Explain the principles of health economics and discuss their application in the development of medicines
  • Evaluate the principles of economics and the methodology behind the statistical and/or data analysis tools used for health economics

Applied Research Project

Research gives scientists, practitioners and policymakers essential knowledge to use in making decisions. Participants will be actively encouraged to contribute to this process and practice it in their professional lives through the research activity that forms a core component of the MSc. in Pharmaceutical Medicine.

The general aims of the applied research project are to develop conceptual and academic rigour in applied research, and to develop participants’ ability in the identification, analysis and presentation of independent applied research through appropriate inferences and recommendations in one of the key subject areas within pharmaceutical medicine.

At the end of the research project, the participant will be able to:

  • Comprehend the principle steps in pharmaceutical research and development based on incomplete and often contradictory data and objectives
  • Evaluate the suitability of research methodologies for the purpose of undertaking research in pharmaceutical medicine
  • Demonstrate expertise in formulating, conducting and reporting an independent and ethical research project
  • Critically review and interpret the literature relating to drug research and development
  • Demonstrate the ability to formulate and employ effective and ethical leadership tools in Pharmaceutical Medicine by completing a substantial body of research
  • Demonstrate the ability to analyse and evaluate data, information and/or surveyed opinions gathered (depending on the nature of the research project) and discuss findings at a level appropriate to a 30 ECTS, Level 9 research project

It should be noted that if a participant does not complete the research project, he or she can still graduate with a Post Graduate Diploma in Pharmaceutical Medicine.

PharmaTrain Centre of Excellence

Course Structure

Hibernia College’s online Master of Science in Pharmaceutical Medicine is comprised of 10 modules plus a research project. On successful completion of the 10 modules, the student is awarded a Postgraduate Diploma in Pharmaceutical Medicine. If the student wishes to progress to the Master’s award, they must then complete a research project.

The Postgraduate Diploma typically takes 20 months to complete. The full Masters programme then typically takes an additional 8 months. Assessment is through a combination of exams, continuous assessment and final thesis.

Click the image below to view the course structure diagram.

M.Sc. in Pharmaceutical Medicine Course Structure

PharmaTrain Centre of Excellence

Course Calendar (Provisional)

The following is a provisional timetable for the Pharmaceutical Medicine programme. Note however that these dates and events are subject to change:

Module Start date End date

Clinical Trials, Knowledge Management & Statistics 1
28th Apr 2014 14th July 2014
Clinical Trials, Knowledge Management & Statistics 2 28th Apr 2014 14th July 2014
Leadership & Negotiation Onsite (Optional)
2nd June 2014 6th June 2014
Leadership & Negotiation Online
4th Aug 2014 6th Oct 2014
Health Economics
4th Aug 2014 20th Oct 2014
Ethics Onsite (Optional) TBC TBC
Discovery & Formulations of New Medicine
27th Oct 2014 1st Dec 2014
Drug Development & Therapeutics
8th Dec 2014 13th Apr 2015
Research Methods
9th Feb 2015 13th Apr 2015
Ethics Online 27th Apr 2015 6th Jul 2015
CCPM
27th Apr 2015 6th Jul 2015
Pharmacovigelance 3rd Aug 2015 5th Oct 2015
Regulatory Affairs 3rd Aug 2015 5th Oct 2015
Thesis 14th Sept 2015 25th Apr 2016

PharmaTrain Centre of Excellence

Entry Requirements

Minimum Entry Requirements

  • An honours primary degree (Level 8 according to the Bologna Qualifications Framework)*
  • Experience working in the medical, pharmaceutical or biotechnology industries

Applications from candidates who do not have the minimum entry requirements will be considered on the basis of their experience in the pharmaceutical industry, other qualifications and an interview, subject to HETAC regulations.

* For more information about the Bologna Qualifications Framework, please visit the European Commission website here and the National Framework of Qualifications website here.

Additional Requirements for Non-Native English Speakers

As all tuition and examinations at Hibernia College are conducted through English, prospective students whose mother tongue is not English will need to demonstrate that they have sufficient language skills to cope with the academic demands of their course and benefit fully from their period of study.

Acceptable English language credentials include:

  • IELTS (International English Language Testing System), minimum score of 6.5 including a minimum of 6.0 in academic English
  • TOEFL (Test of English as a Foreign Language) paper-based test, minimum score of 600 including a minimum of 475 in written English
  • TOEFL (Test of English as a Foreign Language) Internet-based test, minimum score of 94 including a minimum of 24 in written English
  • CSE English, Grade 1 Pass
  • GCE ‘O’ Level English Language, minimum Grade C
  • GCSE English Language, minimum Grade C
  • Hong Kong Certificate in Education, English Language Syllabus B, minimum Grade C
  • Irish Leaving Certificate English, minimum Ordinary Level D3
  • Joint Matriculation Board (JMB) Test in English (Overseas) Examination, Pass
  • University of Cambridge ESOL Examinations, Proficiency: minimum Grade C, Advanced: minimum Grade B

Note that for all proficiency tests the results must be less than two years old. Other evidence of proficiency in English may be accepted including an undergraduate or postgraduate degree taught and assessed through English. Further details can be obtained from the Office for Academic Affairs by emailing academicaffairs@hiberniacollege.net

PharmaTrain Centre of Excellence

Faculty

Programme faculty includes:

Mr. Jeremy Whitty – Programme Director
Dr. Jane Barrett

Dr. Marian Brennan
Dr. Dermot Cox

Dr. Anthony J. Chubb
Dr. Dolores Dooley

Dr. Tim Grant
Ms. Kathy Heard

Dr. Stephanie J. Jones

Prof. Brian S. Mandell

Mr. Carl Naraynassamy
Dr. Hugh O’Doherty

Dr. Eleanor O’Higgins

Ms. Mary Rafter
Prof. David Smith
Dr. Stephen D. Stoller

Mr. Jeremy Whitty – Programme Director

Jeremy Whitty is the Programme Director of the M.Sc. in Pharmaceutical Medicine at the School of Health Sciences, Hibernia College, Dublin and is Professor of Operations and Quality in the Life Sciences at IE Business School, Madrid.

As well as extensive academic experience in the Life Sciences, Jeremy has over 17 years industrial experience working with such companies as Wyeth Biotech (now Pfizer),  Medtronic and Bausch & Lomb.  His research includes the application of best practices in decision engineering to drug development, especially from Proof of Concept to the end of Phase IIb. He is currently conducting doctoral research at Trinity College Dublin.

Dr. Jane Barrett

Dr. Jane Barrett, MBBS, FFPM, LLM qualified in medicine in 1976 and began work as a family doctor. In 1985 she joined the pharmaceutical industry, working for large and small pharmaceutical companies and then for a global Contract Research Organisation.

In 2001 she was awarded a Master’s degree (LLM) in Medical Law after a study sabbatical. She was particularly interested in the legal and ethical aspects of clinical research, and her dissertation was on the use of vulnerable patient groups in research.

Jane is the immediate past Chairman of the British Association of Pharmaceutical Physicians, and is Registrar of the Faculty of Pharmaceutical Medicine.

Dr. Barrett founded the Barrett Consultancy in 2001, and provides medical and legal expertise to pharmaceutical companies. She is also Consultant Medical Adviser and Director to MedicoLegal Investigations Ltd, a UK-based company investigating alleged fraud and misconduct in clinical research.

Dr. Marian Brennan

Dr. Marian Brennan completed her undergraduate degree in Medical Biochemistry at the University of Cape Town, South Africa, majoring in genetics and microbiology. She completed her Ph.D. at the Royal College of Surgeons in Ireland, investigating the mechanisms of interaction between Staphylococci and platelets. Current research is focussed on the development of novel drugs to treat the thrombotic events associated with staphylococcal infections, as well as novel anti-bacterial agents.

Dr. Dermot Cox

Dr. Dermot Cox is a lecturer in the School of Pharmacy in the Royal College of Surgeons in Ireland. His research interests include the role of infection in thrombosis and the clinical development of GPIIb/IIIa antagonists.

Dr. Anthony J. Chubb

Dr. Anthony J. Chubb obtained his Ph.D. in 2002 at the University of Cape Town and is currently a postdoctoral fellow in the Department of Clinical Pharmacology at the Royal College of Surgeons in Ireland. Trained as a molecular biologist, his projects include isolation of novel surface proteins in mycobacterium tuberculosis, using mutagenesis to define the sheddase recognition site of ACE and the PGG2 binding site of COX, and the development of novel NSAID inhibitors of COX. His interests are in structural biology and drug design, especially pharmacophore-based chemoinformatics. Dr. Chubb is co-founder of the consultancy Molecular Biology Solutions Ireland Ltd.

Dr. Dolores Dooley

Dr. Dolores Dooley lectures in philosophy and specialises in bioethics. Born in Chicago, Illinois, she received her Ph.D. in 1974 from the University of Notre Dame, USA. She taught in the US at Mundelein College, Chicago, and Notre Dame University before moving to Ireland.

Dr. Tim Grant

Dr. Tim Grant is a graduate of the University of Wisconsin-Madison, where he studied Biostatistics (MS) and Educational Psychology (PhD). He is currently working as a biostatistician for the Centre for Support and Training of Analysis and Research (CSTAR) located in the School of Public Health, Physiotherapy and Population Sciences at University College Dublin. At the centre, Tim conducts consulting and short courses assisting biomedical researchers across Ireland improve the quality of their research. He is also a chartered statistician (CStat) and scientist (CSci) through the Royal Statistical Society. Tim has been involved in the research process using both qualitative and quantitative methods for over 15 years. In addition to his experience in biomedical research, he has conducted research in the fields of education, business and mechanical engineering.

Ms. Kathy Heard

Kathy Heard is a graduate of Hibernia College’s M.Sc. in Pharmaceutical Medicine and has a Bachelor of Commerce from McMaster (Canada). She has worked in the pharmaceutical industry for 15 years, starting in regulatory affairs with a small dental company. For the past 12 years, she has worked at sanofi pasteur in the clinical department located in Toronto, Canada. During her career at sanofi pasteur, she has been a clinical research associate (CRA), a trial manager, a project manager and a global trainer. Kathy has been responsible for trials conducted in Mexico, Canada, Australia, Brazil and the US, and has been a key contributor to Biologic Licensing Applications in the US and CTDs in Canada and Europe. Currently, her responsibilities include managing the study management platform, working with outsourcing partners and participating on oversight committees for ECD and IVRS.

Dr. Stephanie J. Jones

Dr. Stephanie-Jayne Jones (BClinSci MBChB MRCP DipPharmMed) worked in the NHS for five years, gaining experience in psychiatry, A&E and paediatrics. She joined the pharmaceutical industry in 2001 and has worked in medical affairs and drug safety for a number of different companies, including Abbott Laboratories, GlaxoSmithKline and, more recently, a biotechnology company called Renovo. There, she managed the Medical Affairs and Pharmacovigilance department and was the sole company pharmaceutical physician. She now has a baby daughter and is working as a part-time GP registrar in Cheshire, but wishes to keep an interest in pharmaceutical medicine.

Prof. Brian S. Mandell

Prof. Brian S. Mandell is a senior lecturer in Public Policy and Director of the Negotiation Project at the Kennedy School Government at Harvard University. He is also Chair of the Wexner-Israel and Kokkalis Fellowship programmes at the school. His current teaching and research address the theory and practice of negotiation, emphasising third-party facilitation and consensus-building in domestic and international protracted policy disputes. He writes about contentious disputes and is completing a book on scenario planning for conflict managers and negotiation practitioners. Before coming to Harvard, Prof. Mandell taught at the Norman Paterson School of International Affairs at Carleton University in Ottawa. Previously, he was a strategic analyst for the Canadian Department of National Defense, specialising in UN peacekeeping and the implementation of arms control agreements. A Pew Faculty Fellow and Senior Research Associate at the Kennedy School’s Belfer Center for Science and International Affairs, Prof. Mandell holds a PhD from the University of Toronto.

Mr. Carl Naraynassamy

Carl Naraynassamy MAEd (Brunel), LLB (Lond), BSc (Lond) is an independent consultant in education and training of clinical research and pharmaceutical medicine. His whole 29-year career has been spent working in training institutions or in the pharmaceutical industry, mostly in roles related to drug development. He specialises in the audits of professional education and the development of competency workshops.

Dr. Hugh O’Doherty

Dr. Hugh O’Doherty teaches courses in leadership and conflict resolution. He has been program director at the Glencree Center for Peace and Reconciliation in Ireland, director of the Northern Ireland Inter-Group Relations Project, and director of the Ireland-U.S. Public Leadership Program at the James McGregor Burns Academy of Leadership, University of Maryland. Dr. O’Doherty has consulted on conflict resolution and leadership to a wide range of organisations in Ireland, the United States, Cyprus, and Canada.

Dr. Eleanor O’Higgins

Dr. Eleanor O’Higgins (BA, MSc, MBA, PhD) is on the faculty of the Business School at UCD and a visiting fellow at the London School of Economics and Political Science. She specialises in teaching, research and publications in business ethics, corporate governance, corporate social responsibility and strategic management.

She is a director of Transparency International Ireland and a member of the ethics committee of the US Academy of Management, the United Nations Global Compact Learning Forum, the Board of Management of the Institute of Directors’ Centre for Corporate Governance at University College Dublin and of the advisory board of Centro de Excelencia en Gobierno Corporativo (Centre of Excellence in Corporate Governance) in Mexico. She is also on the editorial boards of a number of international management journals.

Dr. O’Higgins carries out numerous teaching and speaking assignments internationally and has extensive experience in business through consulting work, her previous managerial career and as a company director.

Ms. Mary Rafter

Mary obtained a Bachelor of Science (Pharmacy) degree from University College Dublin in 1979 and registration as a qualified pharmacist (MPSI) in 1980. She has recently completed a Masters Degree in Pharmaceutical Medicine in Trinity College Dublin.  For 14 years of her 30 year career Mary worked for the Irish Medicines Board (IMB),  the regulatory body responsible for the licensing of medicines in Ireland. With the IMB she was a pharmaceutical assessor  and represented the board on a number of EU Committees.  Her roles in the IMB have alternated with periods in industry, where she held various positions, including Quality Assurance Manager, EU Qualified Person, and from 2004 to 2010 Senior Regulatory Affairs Manager for a global team based in Pfizer Newbridge, Ireland.

Prof. David Smith

Prof. David Smith (B.Phil, B.D., S.T.L., M.A., S.T.D.) is director of the MSc in Healthcare Ethics and Law in the Royal College of Surgeons in Ireland (RCSI), visiting senior lecturer in Medical Ethics in the RCSI and invited senior lecturer in Trinity College Dublin, University College Dublin, University College Cork and the Church of Ireland Theological College. He is also actively involved as an ethics consultant with such groups as CIRCA Healthcare Consulting, the Haughton Institute, Bon Secours Health System, Sisters of Charity of Jesus and Mary Services, the Mercy University Hospital, KARE and the Daughters of Charity Services for People with Intellectual Disability.

Dr. Stephen D. Stoller

Dr. Stephen Stoller’s career encompasses academic teaching and consulting to major institutions in the areas of Health Economics and Finance. Dr. Stoller studied at Harvard University (AB cum laude) and the University of California at Berkeley (MPH, PhD in Economics.) Over his career Dr. Stoller has taught courses in health economics, macro and micro economics, corporate finance, investing, organizational structure, and corporate strategy at the University of California, Berkeley, the University of New Mexico, Pacific Lutheran University, Sacred Heart University, the University of San Francisco, St. Mary’s College of California, California State University at Hayward, CERAM, and the University of Liverpool. Dr. Stoller’s major institutional clients have included Kaiser Permanente, Bank of America, American Express, Morgan Stanley, Merck, Johnson and Johnson, and SRI International.

PharmaTrain Centre of Excellence

Fees and Costs

Full Master’s Programme: €18,900 (approx, US$25,000 depending on exchange rate).

Application Fee: €75.

Option 1: pay in one year
Total amount: €18,900
Deposit required: €1000 (non-refundable)
Balance: €17,900

Option 2: pay over two years
Total amount: €20,160 (€9,600 per year)
Deposit required: €1000 (non-refundable)
Year 1 balance: €9,080
Year 2 fee: €10,080

Option 3: quarterly pay over two years
Total amount: €21,504
Deposit required: €1000 (non-refundable)
Balance: 20,504
Paid every quarter over the two first years, €2,563 per payment.

The College has a number of partial scholarships for qualified students. Please ask for further details.

Modular Approach

Students may also chose to take  individual modules or  the three certificates that make up the taught section of the Masters program.

Fee per Certificate: €6,000 (approx. US$7,700 depending on exchange rate).

Upon successful completion of the three certificates, the student will graduate with a PG Diploma in Pharmaceutical Medicine. However you can complete the research project and graduate with the full Masters award.

Fee for the Research Project: €6,000.

We have a limited number of scholarships for the Certificates.  Again, please ask for further details.

 

If you have a question that isn’t answered on this website, you can

Questions

Will my degree be recognised internationally?

Yes. All awards from HETAC (the Higher Education & Training Awards Council) are recognised internationally.

All graduates receive a diploma supplement along with their parchment, which makes the process of award identification internationally even easier. It is designed to provide a description of the nature, level, context, content and status of the studies that were pursued and successfully completed by the student named on the parchment associated with the diploma supplement.

For more information about diploma supplements and the international recognition of our awards, visit the HETAC website here and the European Commission website here.

Is the course 100% online?

The course can be taken 100% online – however, we encourage students to attend the two on-site modules:

  • The Business & Pharmaceutical Ethics module can be taken as an intensive 5-day course in Dublin where it is delivered in collaboration with faculty from the Royal College of Surgeons in Ireland. This coincides with the course induction.
  • The Leadership & Authority module can be taken as an on-site 5-day course in Boston, USA.

For more details, see the provisional course calendar here.

Are there concessions for mature students?

No. All applicants must meet the same minimum entry requirements to be considered for admission to the programme.

English is not my native language. Can I still apply to Hibernia College?

Yes. However, as all tuition and examinations at Hibernia College are conducted through English, prospective students whose mother tongue is not English will need to demonstrate that they have sufficient language skills to cope with the academic demands of their course and benefit fully from their period of study.

Acceptable English language credentials include:

  • IELTS (International English Language Testing System), minimum score of 6.5 with a minimum of 6.0 in academic English
  • TOEFL (Test of English as a Foreign Language), minimum score of 600 with a minimum of 475 in written English
  • CSE English, Grade 1 Pass
  • GCE ‘O’ Level English Language, minimum Grade C
  • GCSE English Language, minimum Grade C
  • Hong Kong Certificate in Education, English Language Syllabus B, minimum Grade C
  • Irish Leaving Certificate English, minimum Ordinary Level D3
  • Joint Matriculation Board (JMB) Test in English (Overseas) Examination, Pass
  • University of Cambridge ESOL Examinations, Proficiency: minimum Grade C, Advanced: minimum Grade B

Note that for all proficiency tests the results must be less than two years old. Other evidence of proficiency in English may be accepted. Further details can be obtained from the Office for Academic Affairs by emailing academicaffairs@hiberniacollege.net

Course Information Request

  • This field is for validation purposes and should be left unchanged.

Master of Science in Pharmaceutical Medicine (MSc)

Partners

Course List